Atomic force microscopy based nanoassay: A new method to study α-Synuclein-dopamine bioaffinity interactions

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Corvaglia, Stefania ^a,b   Sanavio, Barbara ^a,c,e   Hong Enriquez, Rolando P ^c   Sorce, Barbara ^d,f   Bosco, Alessandro ^a   Scaini, Denis ^a,b   Sabella, Stefania ^d   Pompa, Pier Paolo ^d   Scoles, Giacinto ^a,c   Casalis, Loredana ^a  

^a NanoInnovation Laboratory Elettra Sincrotrone Trieste SCpA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GOLD; METAL NANOPARTICLE; PROTEIN BINDING;

ADSORPTION; ATOMIC FORCE MICROSCOPY; BINDING SITE; CHEMISTRY; NANOTECHNOLOGY; PROCEDURES; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADSORPTION; ALPHA-SYNUCLEIN; BINDING SITES; DOPAMINE; GOLD; METAL NANOPARTICLES; MICROSCOPY, ATOMIC FORCE; NANOTECHNOLOGY; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; SENSITIVITY AND SPECIFICITY;

EID: 84903190125     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05366     Document Type: Article

References (35)

1. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501 (2001). (Pubitemid 33676584)
2. Galvin, J. E. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol. 112, 115-26 (2006).
3. Conway, K. a., Rochet, J. C., Bieganski, R. M. & Lansbury, P. T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-9 (2001). (Pubitemid 33063102)
4. Tompkins, M. M., Basgall, E. J., Zamrini, E. & Hill, W. D. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am. J. Pathol. 150, 119-31 (1997). (Pubitemid 27027103)
5. Goldberg, M. S. & Lansbury Jr, P. T. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2, E115-E119 (2000).
6. Conway, K. A.,Harper, J. D.&Lansbury, P. T. Fibrils Formed in Vitro from alpha-Synuclein and Two Mutant Forms Linked to Parkinson's Disease are Typical Amyloid. Biochemistry 39, 2552-2563 (2000). (Pubitemid 30148907)
7. Martinez-Vicente, M. et al. Dopamine-modified a-synuclein blocks chaperonemediated autophagy. J. Clin. Invest. 118, 777-788 (2008).
8. Rivers, R. C. et al. Molecular determinants of the aggregation behavior of alpha-and beta-synuclein. Protein Sci. 17, 887-898 (2008). (Pubitemid 351629583)
9. Bertoncini, C. W. et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 102, 1430-1435 (2005). (Pubitemid 40209187)
10. Dedmon, M. M., Lindorff-Larsen, K., Christodoulou, J., Vendruscolo, M. & Dobson, C. M. Mapping long-range interactions in alpha-synuclein using spinlabelNMRand ensemble molecular dynamics simulations. J. Am. Chem. Soc. 127, 476-7 (2005). (Pubitemid 40174345)
11. Uversky, V. N., Gillespie, J. R. & Finka L. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 41, 415-27 (2000).
12. Davidson, W. S., Jonas, a., Clayton, D. F. & George, J. M. Stabilization of alphasynuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9 (1998).
13. Dikiy, I. & Eliezer, D. Folding and misfolding of alpha-synuclein on membranes. Biochim. Biophys. Acta 1818, 1013-8 (2012).
14. Vilar, M. et al. The fold of a-synuclein fibrils. Proc. Natl. Acad. Sci. 105, 8637-8642 (2008).
15. Apetri, M. M., Maiti, N. C., Zagorski, M. G., Carey, P. R. & Anderson, V. E. Secondary structure of alpha-synuclein oligomers: characterization by raman and atomic force microscopy. J. Mol. Biol. 355, 63-71 (2006). (Pubitemid 41774139)
16. Kang, T. et al. Characterization of surface-confined alpha-synuclein by surface plasmon resonance measurements. Langmuir 22, 13-7 (2006). (Pubitemid 43063515)
17. Van Geel, W. J. A. et al. A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J. Neurosci. Methods 168, 182-185 (2008).
18. An, Y. et al. A photoelectrochemical immunosensor based on au-doped TiO2 nanotube arrays for the detection of a-synuclein. Chem.-A Eur. J. 16, 14439-14446 (2010).
19. Norris, E. H. et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280, 21212-9 (2005). (Pubitemid 40805683)
20. Ostuni, E., Chapman, R. G., Holmlin, R. E., Takayama, S. & Whitesides, G. M. A survey of structure-property relationships of surfaces that resist the adsorption of protein. Langmuir 17, 5605-5620 (2001). (Pubitemid 35330800)
21. Liu,M., Amro, N. A. & Liu, G. Nanografting for surface physical chemistry. Annu. Rev. Phys. Chem. 59, 367-386 (2008). (Pubitemid 351703391)
22. Staii, C., Wood, D. & Scoles, G. Ligand-induced structural changes in maltose binding proteins measured by atomic force microscopy. Nano Lett. 8, 2503-2509 (2008).
23. Bano, F. et al. Toward multiprotein nanoarrays using nanografting and DNA directed immobilization of proteins. Nano Lett. 9, 2614-18 (2009).
24. Sanavio, B. et al. Oriented immobilization of prion protein demonstrated via precise interfacial nanostructure measurements. ACS Nano 4, 6607-16 (2010).
25. Mirmomtaz, E. et al. Quantitative Study of the Effect of Coverage on the Hybridization Efficiency of Surface-Bound DNA Nanostructures. Nano 8, 4134-4139 (2008).
26. Munishkina, L. A., Phelan, C., Uversky, V. N. & Fink, A. L. Conformational behavior and aggregation of a-synuclein in organic solvents: Modeling the effects of membranes. Biochemistry 42, 2720-2730 (2003). (Pubitemid 36330626)
27. Anderson, V. L., Ramlall, T. F., Rospigliosi, C. C., Webb, W. W. & Eliezer, D. Identification of a helical intermediate in trifluoroethanol-induced alphasynuclein aggregation. PNAS 107, 18850-18855 (2010).
28. Nath, S., Meuvis, J., Hendrix, J., Carl, S. a. & Engelborghs, Y. Early aggregation steps in alpha-synuclein as measured by FCS and FRET: evidence for a contagious conformational change. Biophys. J. 98, 1302-11 (2010).
29. Giasson, B. I. et al. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J. Neurosci. Res. 59, 528-533 (2000). (Pubitemid 30090580)
30. Croisier, E. et al. Comparative study of commercially available anti-alphasynuclein antibodies. Neuropathol. Appl. Neurobiol. 32, 351-356 (2006).
31. Herrera, F. E. et al. Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS One 3, e3394 (2008).
32. Dibenedetto, D., Rossetti, G., Caliandro, R. & Carloni, P. A molecular dynamics simulation-based interpretation of nuclear magnetic resonance multidimensional heteronuclear spectra of a-synuclein?dopamine adducts. Biochemistry 52, 6672-83 (2013).
33. Hegner, M., Wagner, P. & Semenza, G. Ultralarge atomically flat templatestripped Au surfaces for scanning probe microscopy. Surf. Sci. 291, 39-46 (1993).
34. Meuvis, J., Gerard, M., Desender, L., Baekelandt, V. & Engelborghs, Y. The conformation and the aggregation kinetics of a-Synuclein depend on the proline residues in Its C-terminal region. Biochemistry 49, 9345-9352 (2010).
35. Copeland, R. A. Enzymes. (Wiley-VCH, Inc., 2000).